<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Introduction: Preparations of intravenous immunoglobulin (IVIG) are used as treatment in different diseases such primary and secondary <z:hpo ids='HP_0002721'>immunodeficiencies</z:hpo>, <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo>, systemic <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory diseases</z:e>, <z:e sem="disease" ids="C0009450" disease_type="Disease or Syndrome" abbrv="">infectious diseases</z:e> and allergic diseases among others </plain></SENT>
<SENT sid="1" pm="."><plain>Objective: to present 13 of our cases with the use of IVIG in different <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Patients and methods: we retrospectively studied 13 patients (10 women and 3 men), mean age 29 years with different <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e>, that underwent conventional treatments without positive response </plain></SENT>
<SENT sid="3" pm="."><plain>They received IVIG pulses, trying to improve or induce remission of their previous clinical situation </plain></SENT>
<SENT sid="4" pm="."><plain>6/13 patients met criteria for <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), 2/13 had <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (APL)one had polydermatomyositis (PDM), 1 juvenile <z:hpo ids='HP_0001369'>arthritis</z:hpo>, 1 panarteritis nodosa (cutaneous <z:chebi fb="59" ids="53571">PAN</z:chebi>), one <z:e sem="disease" ids="C0272126" disease_type="Disease or Syndrome" abbrv="">Evans syndrome</z:e>, and one with autoimmune <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Results: 7 of them had a positive response to therapy with IGEV evaluated by clinical and biochemical parameters </plain></SENT>
<SENT sid="6" pm="."><plain>They remained with conventional treatments </plain></SENT>
<SENT sid="7" pm="."><plain>One patient received a new IG <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">EV</z:e> pulse after 24 months, because of <z:mp ids='MP_0011164'>panniculitis</z:mp> reactivation </plain></SENT>
<SENT sid="8" pm="."><plain>Clinical and biochemical response was poor in 4 of them, and 2 patients died </plain></SENT>
<SENT sid="9" pm="."><plain>Conclusion: IVIg may be usefull in autoimmune <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e> when conventional therapies have failed </plain></SENT>
<SENT sid="10" pm="."><plain>The therapeutic success is also limited </plain></SENT>
<SENT sid="11" pm="."><plain>Only the 55 percent of our patients had a positive clinical response </plain></SENT>
<SENT sid="12" pm="."><plain>Key words: intravenous immunoglobulin, <z:e sem="disease" ids="C0035435" disease_type="Disease or Syndrome" abbrv="">rheumatic diseases</z:e>, therapeutic efficacy </plain></SENT>
</text></document>